StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultNov 5, 2026, 07:18 AM

Monte Rosa Therapeutics Q3 Revenue $54.4M; Net Income $3.1M

AI Summary

Monte Rosa Therapeutics, Inc. reported its third-quarter financial results, showing a substantial increase in collaboration revenue to $54.4 million and a net income of $3.1 million, a significant turnaround from the previous year's loss. The company's balance sheet reflects a strong increase in marketable securities to $532.5 million, though cash and cash equivalents decreased to $45.2 million. Research and development expenses rose to $45.4 million, indicating continued investment in its pipeline. The company also successfully raised $332.1 million in financing.

Key Highlights

  • Monte Rosa Therapeutics reported $54.4 million in collaboration revenue for Q3 2026.
  • Total assets increased to $697.7 million as of September 30, 2026, up from $448.7 million at year-end 2025.
  • Cash and cash equivalents decreased to $45.2 million from $129.9 million.
  • Marketable securities increased significantly to $532.5 million from $247.2 million.
  • Net income for Q3 2026 was $3.1 million, a significant improvement from a net loss of $27.1 million in Q3 2025.
  • Research and development expenses were $45.4 million for Q3 2026, compared to $36.7 million in Q3 2025.
  • The company raised $332.1 million in net cash from financing activities in the nine months ended September 30, 2026.